GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (2)
  • 1
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 24, No. 1 ( 2015-01-01), p. 308-316
    Abstract: Background:BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1); 308–16. ©2014 AACR.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 4356-4356
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 4356-4356
    Abstract: Radiotherapy is very effective at local control of tumours but leads to adverse reactions in a minority of patients. This project aimed to predict which breast cancer patients will show radiation toxicity, allowing them to be offered alternative treatment (e.g. mastectomy). Previously, studies have focussed on single nucleotide polymorphisms (SNP) for association with adverse reactions, but there is growing evidence that genomic copy number variation (CNV) are frequent and significantly contribute to genetic variation and human diseases. The aim of this candidate gene association study was to determine copy number variants (CNVs) that influence radiation toxicity in cancer patients, and combine these with clinical indicators to contribute to a predictive algorithm. CNV data for 88 candidate genes were ranked based on CNV position, size and frequency. Paralogue ratio test (PRT) assays were designed for the top-ranked 13 genes. Typing of the CNVs in the analysed samples was performed using PRT method because it is cheap, simple and fast and requiring a small amount of genomic DNA. Copy number typing was carried out on 69 control samples (comprising 30 random DNA and 39 CEPH [Centre de ‘Etude du Polymorphisme Humain] specimens of three multigenerational reference families); and 401 samples from a breast cancer cohort (i.e. test samples) with good clinical characterisation and scored for late effects of radiotherapy. Two PRT assays in the DNA ligase 1 (LIG1) gene were used for typing. PRT amplification products were electrophoresed on agarose gel (PRT2 assay) and ABI 3031xl genetic analyser (PRT3 assay) respectively. Quantification of DNA bands was performed using Syngene and Genescan software respectively and statistical analysis in SPSS. The result of this study showed that 5.2 % of the CEPH samples and 0.3% of the breast cancer cohorts showed consistent evidence of raised copy numbers which suggest duplication of LIG1 gene in those samples. The result also showed moderate correlation between the two assays used (r=0.56). The findings from this study have re-inforced the need for future research to focus on further characterisation of this studied CNV either by using more PRT over a wider region around LIG1 or an array or sequence based approach. Future work would also attempt to establish whether cells from the breast cancer patients show changed expression of LIG1. Lastly, CNV typing would be repeated in further cohorts, though with a frequency of 0.3%, many more cohorts in the range of thousands might be required. With multiple patients with the variant, then it might be possible to detect significant differences in radiation toxicity phenotypes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4356. doi:1538-7445.AM2012-4356
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...